This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2003 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: January 27, 2003
Last updated: July 4, 2009
Last verified: March 2003

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.

Condition Intervention Phase
Lymphoma Drug: cisplatin Drug: cytarabine Drug: methylprednisolone Drug: pixantrone dimaleate Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase I Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin in the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: February 2002
Detailed Description:


  • Determine the maximum tolerated dose and recommended dose of pixantrone when administered with cytarabine, methylprednisolone, and cisplatin in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
  • Determine the dose-limiting toxic effects of this regimen in these patients.
  • Determine the relationship between toxicity and systemic exposure to this regimen in these patients.
  • Determine the safety of this regimen in these patients.
  • Assess the pharmacokinetics of this regimen in these patients.
  • Determine, preliminarily, the efficacy of this regimen in these patients.

OUTLINE: This is an open-label, non-randomized, multicenter, dose-escalation study of pixantrone.

Patients receive pixantrone IV over 1 hour on day 1, methylprednisolone IV over 15 minutes on days 1-5, cisplatin IV over 30 minutes on days 1-4, and cytarabine IV over 2 hours on day 5. Treatment repeats every 21 days for at least 8 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of pixantrone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 2 of 6 patients experience dose-limiting toxicity. Additional patients are treated at the recommended dose, which is defined as the dose preceding the MTD.

Patients are followed every 3 months.

PROJECTED ACCRUAL: Approximately 3-30 patients will be accrued for this study.


Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) including the following:

    • Diffuse large B-cell lymphoma
    • Transformed NHL
    • Follicular large cell lymphoma
    • Peripheral T-cell lymphoma
    • Unclassified aggressive histology (immunoblastic lymphoma)
  • Must have received 1 to 3 prior chemotherapy treatment regimens (may include doxorubicin up to a cumulative dose of no greater than 450 mg/m^2)
  • No Burkitt's lymphoma, lymphoblastic lymphoma, or mantle cell lymphoma



  • 18 to 64

Performance status

  • WHO 0-1

Life expectancy

  • At least 3 months


  • Neutrophil count at least 1,500/mm^3*
  • Platelet count at least 100,000/mm^3* NOTE: *Lower values may be accepted if evidence of bone marrow involvement


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)**
  • Alkaline phosphatase no greater than 2 times ULN**
  • AST or ALT no greater than 2 times ULN**
  • No history or clinical symptoms of hepatitis B or C virus NOTE: **Higher values may be accepted if evidence of liver involvement


  • Creatinine no greater than 1.5 mg/dL


  • LVEF at least 50% by MUGA
  • No clinically significant cardiovascular abnormalities
  • No New York Heart Association class II-IV heart disease
  • No myocardial infarction within the past 6 months
  • No severe arrhythmia
  • No uncontrolled hypertension


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for at least 6 months after study
  • No history or clinical symptoms of HIV
  • No clinically significant neurological abnormalities
  • No serious uncontrolled infection (NCI CTC grade 3-4)
  • No condition that would place the patient at undue risk or interfere with the study results


Biologic therapy

  • At least 3 months since prior radioimmunotherapy


  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy
  • At least 1 year since prior platinum or cytarabine (unless complete response to treatment)
  • At least 2 years since prior fludarabine or nitrosoureas
  • No prior cumulative cisplatin greater than 600 mg/m^2

Endocrine therapy

  • Not specified


  • See Biologic therapy
  • At least 4 weeks since prior radiotherapy
  • No prior radiotherapy to the whole pelvis


  • At least 1 week since prior minor surgery and recovered
  • At least 4 weeks since prior major thoracic and/or abdominal surgery and recovered


  • At least 1 month since prior investigational drugs
  • Recovered from prior therapy
  • No other concurrent investigational drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00053105

United States, Arizona
Arizona Clinical Research Center
Tucson, Arizona, United States, 85712
United States, Arkansas
Highlands Oncology Group
Springdale, Arkansas, United States, 72764
United States, California
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States, 90033-0800
United States, Maryland
Marlene and Stewart Greenebaum Cancer Center, University of Maryland
Baltimore, Maryland, United States, 21201
United States, Ohio
Ireland Cancer Center
Cleveland, Ohio, United States, 44106-5055
United States, Tennessee
Boston Baskin Cancer Group, University Tennessee
Memphis, Tennessee, United States, 38104
United States, Texas
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Study Chair: Luis Fayad, MD M.D. Anderson Cancer Center
  More Information Identifier: NCT00053105     History of Changes
Other Study ID Numbers: CDR0000269140
Study First Received: January 27, 2003
Last Updated: July 4, 2009

Keywords provided by National Cancer Institute (NCI):
recurrent adult diffuse large cell lymphoma
recurrent grade 3 follicular lymphoma
recurrent cutaneous T-cell non-Hodgkin lymphoma
recurrent adult immunoblastic large cell lymphoma

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Methylprednisolone Hemisuccinate
Prednisolone acetate
Methylprednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Inflammatory Agents
Autonomic Agents processed this record on August 18, 2017